BME SEC फाइलिंग - BlackRock Health Sciences Trust- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	4UL0KI4EPYFKMUU31I34
CIK	1314966

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BlackRock Health Sciences Trust

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

May 22, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
February 25, 2025	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Clas
February 25, 2025	EX-99.(A)(5)(III)	Certain BlackRock Funds Announce Final Results of Tender Offers Exhibit (a)(5)(iii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Final Results of Tender Offers New York, February 24, 2025 – The BlackRock closed-end funds (the “Funds”) listed below announced today the final results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
February 25, 2025	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
February 24, 2025	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Clas
February 24, 2025	EX-99.(A)(5)(II)	Fund Name Exhibit (a)(5)(ii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers New York, February 21, 2025 – The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
February 24, 2025	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.00 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
January 22, 2025	EX-99.(A)(1)(III)	Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated January 22, 2025 Exhibit (a)(1)(iii) Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated January 22, 2025 ALL TENDER REQUESTS MUST BE RECEIVED IN PROPER FORM ON OR BEFORE 5:00 P.
January 22, 2025	EX-99.(A)(1)(I)	Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest BlackRock Health Sciences Trust 98% of Net Asset Value Per Share BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT Table of Contents Exhibit (a)(1)(i) Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust at 98% of Net Asset Value Per Share by BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON FEBRUARY 21, 2025, UNLESS THE OFFER IS EXTENDED. To the Common Shareholders
January 22, 2025	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $13,570,307 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $13,570,307.
January 22, 2025	SC TO-I	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Class of Securities) 0
January 22, 2025	EX-99.(A)(1)(II)	Supplement No. 1 to the Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest BlackRock Health Sciences Trust 98% of Net Asset Value Per Share BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO Exhibit (a)(1)(ii) Supplement No. 1 to the Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust at 98% of Net Asset Value Per Share by BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON FEBRUARY 21, 2025, UNLESS THE OFFER IS EXTENDED. To the Common Shareh
January 21, 2025	EX-10.1	STANDSTILL AGREEMENT Exhibit 10.1 Subject to FRE 408 STANDSTILL AGREEMENT This Standstill Agreement (including the exhibits hereto, this “Agreement”) is entered into as of January 20, 2025 by and among Saba Capital Management, L.P. (“Saba”), BlackRock Health Sciences Trust (the “Fund”) and BlackRock Advisors, LLC (the “Advisor,” and together with Saba and the Fund, the “Parties,” and each individually, a “Party”). WHE
January 21, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 (January 20, 2025) BLACKROCK HEALTH SCIENCES TRUST (Exact Name of Registrant as Specified in Charter) Delaware 811-21702 20-2433262 (State or Other Jurisdiction of In
January 3, 2025	SC TO-C	As filed with the Securities and Exchange Commission on January 2, 2025 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock H SC TO-C As filed with the Securities and Exchange Commission on January 2, 2025 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 23, 2024	424B3	BLACKROCK ALPHA STRATEGIES FUND (BAS) BLACKROCK CORE BOND TRUST (BHK) BLACKROCK CORPORATE HIGH YIELD FUND, INC. (HYT) BLACKROCK CREDIT STRATEGIES FUND (CREDX) BLACKROCK DEBT STRATEGIES FUND, INC. (DSU) BLACKROCK ENHANCED EQUITY DIVIDEND TRUST (BDJ) B Table of Contents Filed Pursuant to Rule 424(b)(3) Registration File Nos.: 333-273507 (BAS) 333-262607 (BHK) 333-262469 (HYT) 333-255980 (CREDX) 333-267429 (DSU) 333-272239 (BDJ) 333-266318 (BGT) 333-263527 (BME) 333-262743 (BKT) 333-263021 (BKN) 333-262366 (BLW) 333-262119 (BIT) 333-259605 (BFK) 333-273508 (BPIF) 333-264682 (BST) 333-262272 (BUI) BLACKROCK ALPHA STRATEGIES FUND (BAS) BLACKROCK CO
November 20, 2024	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Clas
November 20, 2024	EX-99.(A)(5)(III)	Certain BlackRock Funds Announce Final Results of Tender Offers Exhibit (a)(5)(iii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Final Results of Tender Offers New York, November 19, 2024 – The BlackRock closed-end funds (the “Funds”) listed below announced today the final results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
November 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
November 19, 2024	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Tit
November 19, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
November 19, 2024	EX-99.(A)(5)(II)	Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers Exhibit (a)(5)(ii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers New York, November 18, 2024 – The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
October 16, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $14,9 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $14,951,512.
October 16, 2024	EX-99.(A)(1)(I)	Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest BlackRock Health Sciences Trust 98% of Net Asset Value Per Share BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT Table of Contents Exhibit (a)(1)(i) Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust at 98% of Net Asset Value Per Share by BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON NOVEMBER 18, 2024, UNLESS THE OFFER IS EXTENDED. To the Common Shareholders
October 16, 2024	SC TO-I	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Class of Securities) 0
October 16, 2024	EX-99.(A)(1)(II)	Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated October 16, 2024 Exhibit (a)(1)(ii) Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated October 16, 2024 ALL TENDER REQUESTS MUST BE RECEIVED IN PROPER FORM ON OR BEFORE 5:00 P.
October 1, 2024	SC TO-C	As filed with the Securities and Exchange Commission on October 1, 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock H As filed with the Securities and Exchange Commission on October 1, 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
August 21, 2024	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Clas
August 21, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.0001 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
August 21, 2024	EX-99.(A)(5)(III)	Certain BlackRock Funds Announce Final Results of Tender Offers Exhibit (a)(5)(iii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Final Results of Tender Offers New York, August 20, 2024 – The BlackRock closed-end funds (the “Funds”) listed below announced today the final results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
August 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.0001 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I/A (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid — 0.
August 20, 2024	EX-99.(A)(5)(II)	Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers Exhibit (a)(5)(ii) Contact: 1-800-882-0052 Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers New York, August 19, 2024 – The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund’s tender offer (each, a “Tender Offer”) for up to 2.
August 20, 2024	SC TO-I/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer) SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Tit
July 18, 2024	EX-99.(A)(1)(II)	Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated July 18, 2024 Exhibit (a)(1)(ii) Letter of Transmittal Regarding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust Tendered Pursuant to the Offer to Purchase Dated July 18, 2024 ALL TENDER REQUESTS MUST BE RECEIVED IN PROPER FORM ON OR BEFORE 5:00 P.
July 18, 2024	EX-99.(D)(4)	Discount Management Program Standstill Agreement Exhibit (d)(4) Discount Management Program Standstill Agreement This Discount Management Program Standstill Agreement is entered into as of May 3, 2024 (this “Agreement”), by and among Karpus Management, Inc.
July 18, 2024	EX-99.(A)(1)(I)	Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest BlackRock Health Sciences Trust 98% of Net Asset Value Per Share BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT Table of Contents Exhibit (a)(1)(i) Offer to Purchase Up to 2.5% of the Issued and Outstanding Common Shares of Beneficial Interest of BlackRock Health Sciences Trust at 98% of Net Asset Value Per Share by BlackRock Health Sciences Trust in Exchange for Cash THE OFFER TO PURCHASE WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON AUGUST 19, 2024, UNLESS THE OFFER IS EXTENDED. To the Common Shareholders of
July 18, 2024	EX-FILING FEES	Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $15,289,552 Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables SC TO-I (Form Type) BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee rate Amount of Filing Fee Fees to Be Paid $15,289,552.
July 18, 2024	SC TO-I	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Health Sciences Trust (Name of Subject Company (Issuer)) BlackRock Health Sciences Trust (Names of Filing Person(s) (Issuer)) Common Shares of Beneficial Interest, Par Value $0.001 per share (Title of Class of Securities) 0
July 2, 2024	SC TO-C	As filed with the Securities and Exchange Commission on July 1, 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BlackRock Heal SC TO-C As filed with the Securities and Exchange Commission on July 1, 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
June 5, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
August 4, 2023	CORRESP	BRUSSELS CHICAGO FRANKFURT HOUSTON LONDON LOS ANGELES MILAN NEW YORK PALO ALTO PARIS ROME SAN FRANCISCO WASHINGTON 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 August 4, 2023 Mr.
June 27, 2023	424B3	BLACKROCK HEALTH SCIENCES TRUST Supplement dated June 26, 2023 to the Prospectus and Statement of Additional Information (“SAI”), each dated April 25, 2022, as supplemented on July 18, 2022 and January 3, 2023 BlackRock Health Sciences Trust Filed Pursuant to Rule 424(b)(3) Registration File No.
May 23, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive
January 3, 2023	424B3	BLACKROCK CORPORATE HIGH YIELD FUND, INC. (HYT) BLACKROCK CREDIT STRATEGIES FUND (CREDX) BLACKROCK DEBT STRATEGIES FUND, INC. (DSU) BLACKROCK HEALTH SCIENCES TRUST (BME) BLACKROCK HEDGE FUND GUIDED PORTFOLIO SOLUTION (GPS) BLACKROCK INCOME TRUST, INC Filed Pursuant to Rule 424(b)(3) Registration File Nos.: 333-262469 (HYT) 333-255980 (CREDX) 333-267429 (DSU) 333-263527 (BME) 333-251797 (GPS) 333-262743 (BKT) 333-262366 (BLW) 333-262119 (BIT) 333-261023 (BLE) 333-264682 (BST) 333-262272 (BUI) BLACKROCK CORPORATE HIGH YIELD FUND, INC. (HYT) BLACKROCK CREDIT STRATEGIES FUND (CREDX) BLACKROCK DEBT STRATEGIES FUND, INC. (DSU) BLACKROCK HEALTH SCIEN
July 18, 2022	424B3	BLACKROCK HEALTH SCIENCES TRUST Supplement dated July 18, 2022 to the Prospectus and Statement of Additional Information (“SAI”), each dated April 25, 2022 Filed Pursuant to Rule 424(b)(3) Registration File No.: 333-263527 BLACKROCK HEALTH SCIENCES TRUST Supplement dated July 18, 2022 to the Prospectus and Statement of Additional Information (?SAI?), each dated April 25, 2022 This supplement amends certain information in the Prospectus and SAI, each dated April 25, 2022, of BlackRock Health Sciences Trust (the ?Trust?). Unless otherwise indicated, al
June 3, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
May 26, 2022	NPORT-EX	Schedule of Investments Schedule of Investments (unaudited) March 31, 2022 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks Biotechnology — 18.
April 26, 2022	EX-99.(L)(2)	Opinion and Consent of Counsel to the Registrant is filed herewith. MORRIS, NICHOLS, ARSHT & TUNNELL LLP 1201 NORTH MARKET STREET P.O. BOX 1347 WILMINGTON, DELAWARE 19899-1347 (302) 658-9200 (302) 658-3989 FAX April 26, 2022 BlackRock Health Sciences Trust 100 Bellevue Parkway Wilmington, Delaware 19809 Re: BlackRock Health Sciences Trust Ladies and Gentlemen: We have acted as special Delaware counsel to BlackRock Health Sciences Trust, a Delaware statutory trust
April 26, 2022	POS EX	As filed with the Securities and Exchange Commission on April 26, 2022 As filed with the Securities and Exchange Commission on April 26, 2022 Securities Act File No.
April 26, 2022	424B2	BLACKROCK HEALTH SCIENCES TRUST Up to 4,000,000 Common Shares of Beneficial Interest 424B2 1 d269284d424b2.htm BLACKROCK HEALTH SCIENCES TRUST Filed Pursuant to Rule 424(b)(2) Securities Act File No. 333-263527 PROSPECTUS SUPPLEMENT (To Prospectus dated April 25, 2022) BLACKROCK HEALTH SCIENCES TRUST Up to 4,000,000 Common Shares of Beneficial Interest The BlackRock Health Sciences Trust (the “Trust,” “we,” “us” or “our”) is offering for sale up to 4,000,000 of our common shares o
April 26, 2022	EX-99.(H)(1)	Form of Third Amended and Restated Distribution Agreement is filed herewith. Exhibit (h)(1) THIRD AMENDED AND RESTATED DISTRIBUTION AGREEMENT This THIRD AMENDED AND RESTATED DISTRIBUTION AGREEMENT (the ?Agreement?) is made as of April 26, 2022 by and between BlackRock Health Sciences Trust, a Delaware statutory trust (the ?Fund?), and BlackRock Investments, LLC, a Delaware limited liability company (the ?Distributor?).
April 26, 2022	EX-99.(H)(2)	Form of Sub-Placement Agent Agreement is filed herewith. Exhibit (h)(2) SUB-PLACEMENT AGENT AGREEMENT BlackRock Investments, LLC 55 East 52nd Street, New York, New York 10055 April 26, 2022 UBS Securities LLC 1285 Avenue of the Americas New York, New York 10019 RE: At-the-Market Offerings by BlackRock Health Sciences Trust Ladies and Gentlemen: From time to time BlackRock Investments, LLC (the ?Distributor,? ?we? or ?us?) will act as manager of registered at-the-market offerings by BlackRock Health Sciences Trust, a Delaware statutory trust (the ?Fund?), of up to 4,000,000 common shares (the ?Shares?) of beneficial interest, par value $0.
April 26, 2022	EX-99.(S)(3)	Calculation of Filing Fee Tables (Final Prospectus Dated April 26, 2022) is filed herewith. Exhibit (s)(3) Calculation of Filing Fee Tables FORM N-2 (Form Type) BLACKROCK HEALTH SCIENCES TRUST (Exact Name of Registrant as Specified in its Charter) The maximum aggregate amount of common shares of beneficial interest being offered pursuant to the Prospectus Supplement dated April 26, 2022 (the ?Prospectus Supplement?) and the accompanying Base Prospectus dated April 25, 2022 (together with the Prospectus Supplement, the ?Prospectus?) is 4,000,000 common shares of beneficial interest (the ?Offering?).
April 21, 2022	CORRESP	BRUSSELS CHICAGO FRANKFURT HOUSTON LONDON LOS ANGELES MILAN NEW YORK PALO ALTO PARIS ROME SAN FRANCISCO WASHINGTON 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 April 21, 2022 VIA EDGAR David Orlic Division of Investment Management Securities and Exchange Commission 100 F Street, NE Washington, D.
November 24, 2021	NPORT-EX	Schedule of Investments Schedule of Investments (unaudited) September 30, 2021 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks Biotechnology — 20.
July 20, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) DEFA14A 1 d202808ddefa14a.htm BR CLASSIFIED FUND UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
June 8, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 d178928ddef14a.htm CLASSIFIED FUND N&P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
May 27, 2021	NPORT-EX	Schedule of Investments BlackRock Health Sciences Trust Schedule of Investments (unaudited) March 31, 2021 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks Biotechnology — 18.
April 30, 2021	424B2	5,000,000 Shares BlackRock Health Sciences Trust Common Shares PART I INFORMATION ABOUT BLACKROCK HEALTH SCIENCES TRUST Table of Contents Filed pursuant to Rule 424(b)(2) File No. 333-230158 5,000,000 Shares BlackRock Health Sciences Trust Common Shares PART I INFORMATION ABOUT BLACKROCK HEALTH SCIENCES TRUST Item 1. Outside Front Cover 1.a. The registrant?s name is BlackRock Health Sciences Trust (the ?Fund?). 1.b. The Fund is registered under the Investment Company Act of 1940, as amended (the ?1940 Act?), as a d
April 29, 2021	EX-99.(K)(3)	Form of Seventh Amended and Restated Securities Lending Agency Agreement between the Registrant and BlackRock Investment Management, LLC is filed herewith. Exhibit (k)(3) SEVENTH AMENDED AND RESTATED SECURITIES LENDING AGENCY AGREEMENT This Seventh Amended and Restated Agreement, dated as of January 1, 2021, between each investment company, severally and not jointly, identified on Schedule A, as such schedule may be amended from time to time (each a ?Client?), acting on behalf of itself or the funds listed on Schedule A hereto and any future series of a Client (each, a ?Fund?), by and through BlackRock Advisors, LLC (?BlackRock?), not in its individual capacity but as agent and investment advisor, and BlackRock Investment Management, LLC (the ?Lending Agent?), a Delaware limited liability company.
April 29, 2021	EX-99.(G)(6)	Amendment No. 4 to Amended and Restated Master Advisory Fee Waiver Agreement is filed herewith. Execution Version Amendment No. 4 to Amended and Restated Master Advisory Fee Waiver Agreement This AMENDMENT NO. 4 (this ?Amendment?) to the Amended and Restated Master Advisory Fee Waiver Agreement dated December 1, 2019 (the ?Agreement?) is made as of this 24th day of March, 2021, by and among BlackRock Advisors, LLC (the ?Adviser?) and each investment company listed on Schedule A attached here
April 29, 2021	EX-99.(R)	Code of Ethics of the Registrant and the Investment Advisor is filed herewith Exhibit (r) Code of Ethics for Fund Access Persons May 1, 2020 Code of Ethics for Fund Access Persons Effective Date: May 1, 2020 Applies to the following types of Funds registered under the 1940 Act: ? Open-End Mutual Funds (excluding money market funds) ? Money Market Funds ? ETFs ? Closed-End Funds ? Other (Business Development Companies) 1.
April 29, 2021	486BPOS	- BLACKROCK HEALTH SCIENCES TRUST As filed with the Securities and Exchange Commission on April 29, 2021 Securities Act Registration No.
April 29, 2021	EX-99.(B)(2)	Amendment No. 1 to Amended and Restated Bylaws is filed herewith. Exhibit (b)(2) AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF BLACKROCK HEALTH SCIENCES TRUST This Amendment No. 1 (this ?Amendment?) to the Amended and Restated Bylaws of BlackRock Health Sciences Trust effective as of October 28, 2016 (the ?Bylaws?) is made as of November 19, 2020 in accordance with Article VII, Section 1 of the Bylaws. Capitalized terms used herein and not otherwise here
April 29, 2021	EX-99.(G)(4)	Amendment No. 2 to Amended and Restated Master Advisory Fee Waiver Agreement is filed herewith. Exhibit (g)(4) Amendment No. 2 to Amended and Restated Master Advisory Fee Waiver Agreement This AMENDMENT NO. 2 (this ?Amendment?) to the Amended and Restated Master Advisory Fee Waiver Agreement dated December 1, 2019 (the ?Agreement?) is made as of this 18th day of September, 2020, by and among BlackRock Advisors, LLC (the ?Adviser?) and each investment company listed on Schedule A attached her
April 29, 2021	EX-99.(K)(1)	Form of Amended and Restated Transfer Agency and Service Agreement is incorporated herein by reference to Exhibit (k)(1) to Post-Effective Amendment No. 2 to the Registrant’s Registration Statement on Form N-2 (File No. 333-230158), as filed with the SEC on April 29, 2021. Amended and Restated Transfer Agency and Service Agreement Among Each of the BlackRock Closed-End Investment Companies Listed Herein on Appendix A and Computershare Trust Company, N.
April 29, 2021	EX-99.(N)	Consent of independent registered public accounting firm for the Registrant is filed herewith EX-99.(N) 8 d173219dex99n.htm INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT Exhibit (n) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-230158 on Form N-2 of our report dated February 23, 2021, relating to the financial statements and financial highlights of BlackRock Health Sciences Trust (the “Tr
April 29, 2021	EX-99.(G)(5)	Amendment No. 3 to Amended and Restated Master Advisory Fee Waiver Agreement is filed herewith. Exhibit (g)(5) Amendment No. 3 to Amended and Restated Master Advisory Fee Waiver Agreement This AMENDMENT NO. 3 (this ?Amendment?) to the Amended and Restated Master Advisory Fee Waiver Agreement dated December 1, 2019 (the ?Agreement?) is made as of this [?] day of [?], 2021, by and among BlackRock Advisors, LLC (the ?Adviser?) and each investment company listed on Schedule A attached hereto (ea
November 25, 2020	NPORT-EX	Schedule of Investments BlackRock Health Sciences Trust Schedule of Investments (unaudited) September 30, 2020 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks Biotechnology — 20.
August 27, 2020	424B3	BLACKROCK HEALTH SCIENCES TRUST Supplement dated August 27, 2020 to the Prospectus, dated April 29, 2020 BLACKROCK HEALTH SCIENCES TRUST Filed Pursuant to Rule 424(b)(3) Registration File No.
June 9, 2020	DEF 14A	- CLASSIFIED FUND N&P Classified Fund N&P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 1, 2020	NPORT-EX	Schedule of Investments BlackRock Health Sciences Trust Schedule of Investments (unaudited) March 31, 2020 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks — 99.
April 27, 2020	EX-99.(K)(3)	Form of Sixth Amended and Restated Securities Lending Agency Agreement between the Registrant and BlackRock Investment Management, LLC – filed herewith Form of Sixth Amended and Restated Securities Lending Agreement Exhibit (k)(3) SIXTH AMENDED AND RESTATED SECURITIES LENDING AGENCY AGREEMENT This Sixth Amended and Restated Agreement, dated as of January 1, 2020, between each investment company, severally and not jointly, identified on Schedule A, as such schedule may be amended from time to time (each a “Client”), acting on behalf of itself or the funds listed on Schedule A hereto and any future series of a Client (each, a “Fund”), by and through BlackRock Advisors, LLC (“BlackRock”), not in its individual capacity but as agent and investment advisor, and BlackRock Investment Management, LLC (the “Lending Agent”), a Delaware limited liability company.
April 27, 2020	EX-99.(N)	Consent of independent registered public accounting firm for the Registrant – filed herewith Independent Registered Public Accounting Firm Consent CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No.
April 27, 2020	EX-99.(G)(3)	Amendment No. 1 to Amended and Restated Master Advisory Fee Waiver Agreement is incorporated herein by reference to Exhibit (g)(3) to Post-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form N-2 (File No. 333-230158), as filed with the SEC on April 27, 2020. Amendment No. 1 to Amended and Restated Master Advisory Fee Waiver Agreement Exhibit (g)(3) Amendment No. 1 to Amended and Restated Master Advisory Fee Waiver Agreement This AMENDMENT NO. 1 (this “Amendment”) to the Amended and Restated Master Advisory Fee Waiver Agreement dated December 1, 2019 (the “Agreement”) is made as of this 24th day of January, 2020, by and among BlackRock Advisors, LLC (t
April 27, 2020	486BPOS	- BLACKROCK HEALTH SCIENCES TRUST BlackRock Health Sciences Trust As filed with the Securities and Exchange Commission on April 27, 2020 Securities Act Registration No.
April 27, 2020	EX-99.(G)(2)	Amended and Restated Master Advisory Fee Waiver Agreement is incorporated herein by reference to Exhibit (g)(2) to Post-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form N-2 (File No. 333-230158), as filed with the SEC on April 27, 2020. Amended and Restated Master Advisory Fee Agreement Exhibit (g)(2) Amended and Restated Master Advisory Fee Waiver Agreement This AMENDED AND RESTATED MASTER ADVISORY FEE WAIVER AGREEMENT (this “Agreement”) is made as of December 1, 2019, by and among BlackRock Advisors, LLC (the “Adviser”) and each investment company listed on Schedule A attached hereto (each, a “Fund”).
April 27, 2020	EX-99.(R)	Code of Ethics of the Registrant and the Investment Advisor – filed herewith Code of Ethics of the Registrant and the Advisor Code of Ethics for Fund Access Persons Effective Date: April 1, 2019 Applies to the following types of Funds registered under the 1940 Act: ☒ Open-End Mutual Funds (excluding money market funds) ☒ Money Market Funds ☒ iShares ETFs ☒ Closed-End Funds ☒ Other (BCIC) 1.
June 11, 2019	DEF 14A	BGIO / BlackRock 2022 Global Income Opportunity Trust DEF 14A - - CLASSIFIED FUND N&P Classified Fund N&P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 29, 2019	NPORT-EX	BME / BlackRock Health Sciences Trust NPORT-EX - - EX-BME Schedule of Investments (unaudited) March 31, 2019 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) Security Shares Value Common Stocks — 98.
April 24, 2019	CORRESP	BME / BlackRock Health Sciences Trust CORRESP - - BlackRock Health Sciences Trust BlackRock Health Sciences Trust 100 Bellevue Parkway Wilmington, DE 19809 April 24, 2019 VIA EDGAR Division of Investment Management Securities and Exchange Commission 100 F Street, N.
April 19, 2019	CORRESP	BME / BlackRock Health Sciences Trust CORRESP - - BlackRock Health Sciences Trust 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 April 19, 2019 VIA EDGAR Kathy Churko Samantha Brutlag Division of Investment Management Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: BlackRock Health Sciences Trust Registration Statement on Form N-2 (Securities Act File No.
February 13, 2019	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
November 21, 2018	N-Q	BME / BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 21, 2018	EX-99.CERT	CERTIFICATION PURSUANT TO RULE Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
June 6, 2018	DEF 14A	BGIO / BlackRock 2022 Global Income Opportunity Trust CLASSIFIED FUND N&P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
May 22, 2018	N-Q	BME / BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 22, 2018	EX-99.CERT	CERTIFICATION PURSUANT TO RULE EX-99.CERT 2 d490964dex99cert.htm CERTIFICATION PURSUANT TO SECTION 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2.
April 27, 2018	EX-99.2H DISTR CONTR	AMENDED AND RESTATED SUB-PLACEMENT AGENT AGREEMENT BlackRock Investments, LLC 55 East 52nd Street, New York, New York 10055 Exhibit (h)(4) AMENDED AND RESTATED SUB-PLACEMENT AGENT AGREEMENT BlackRock Investments, LLC 55 East 52nd Street, New York, New York 10055 September 5, 2017 UBS Securities LLC 1285 Avenue of the Americas New York, New York 10019 RE: At-the-Market Offerings by BlackRock Health Sciences Trust Ladies and Gentlemen: From time to time BlackRock Investments, LLC (the “Distributor”, “we” or “us”) will act as manager of registered at-the-market offerings by BlackRock Health Sciences Trust, a Delaware statutory trust (the “Fund”), of up to 2,500,000 common shares (the “Shares”) of beneficial interest, par value $0.
April 27, 2018	EX-99.2H DISTR CONTR	Second Amended and Restated Distribution Agreement between the Registrant and BlackRock Investments, LLC is incorporated herein by reference to Exhibit (h)(2) to Post-Effective Amendment No. 2 to the Registrant’s Registration Statement on Form N-2, as filed with the SEC on April 27, 2018. Exhibit (h)(2) SECOND AMENDED AND RESTATED DISTRIBUTION AGREEMENT This SECOND AMENDED AND RESTATED DISTRIBUTION AGREEMENT (the “Agreement”) made as of September 5, 2017 by and between BlackRock Health Sciences Trust, a Delaware statutory trust (the “Fund”), and BlackRock Investments, LLC, a Delaware limited liability company (the “Distributor”).
April 27, 2018	EX-99.2N OTH CONSENT	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit (n) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Post-Effective Amendment No.
April 27, 2018	486BPOS	BME / BlackRock Health Sciences Trust 486BPOS As filed with the Securities and Exchange Commission on April 27, 2018 Securities Act Registration No.
April 27, 2018	EX-1	POWER OF ATTORNEY Exhibit (s)(3) POWER OF ATTORNEY The undersigned Trustee of BlackRock Health Sciences Trust (the "Trust") hereby appoints John M.
April 27, 2018	EX-99.2G ADVSR CONTR	Closed-End Fund Master Advisory Fee Waiver Agreement Exhibit (g)(2) Closed-End Fund Master Advisory Fee Waiver Agreement This MASTER ADVISORY FEE WAIVER AGREEMENT (this “Agreement”) is made as of the 2nd day of December, 2016, by and among BlackRock Advisors, LLC (the “Adviser”) an “Adviser”) and each investment company listed on Schedule A attached hereto (each, a “Fund”).
February 16, 2018	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints Janey Ahn, Benjamin Archibald, Aaron Wasserman, Eugene Drozdetski, Jessica Herlihy, Gladys Chang, Kiersten Zaza, Charles Park and Tricia Meyer of BlackRock, Inc.
February 13, 2018	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
November 22, 2017	EX-99.CERT	CERTIFICATION PURSUANT TO RULE EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statemen
November 22, 2017	N-Q	Blackrock Health Sciences Trust - BLACKROCK HEALTH SCIENCES TRUST BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 7, 2017	DEF 14A	BlackRock MuniAssets Fund CLASSIFIED FUND N&P Classified Fund N&P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 23, 2017	EX-99.CERT	CERTIFICATION PURSUANT TO RULE EX-99.CERT 2 d369527dex99cert.htm CERTIFICATION PURSUANT TO SECTION 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2.
May 23, 2017	N-Q	Blackrock Health Sciences Trust - BLACKROCK HEALTH SCIENCES TRUST N-Q 1 d369527dnq.htm BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent
April 25, 2017	EX-99.2N OTH CONSENT	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.2N OTH CONSENT 4 ex-n.htm EXHIBIT (N) - CONSENT CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Post-Effective Amendment No. 1 to Registration Statement No. 333-210770 on Form N-2 of our report dated February 23, 2017, relating to the financial statements and financial highlights of BlackRock Health Sciences Trust (the “Trust”), a
April 25, 2017	EX-99.2K OTH CONTRCT	ADMINISTRATIVE SERVICES AGREEMENT Exhibit (k)(2) EXECUTION COPY ADMINISTRATIVE SERVICES AGREEMENT THIS AGREEMENT (the ?Agreement?) is dated as of December 29, 2000 by and among STATE STREET BANK AND TRUST COMPANY, a Massachusetts trust company (?State Street?), and each entity listed on Schedule I hereto, together with any other entity which may from time to time become a party to this Agreement by execution of an Instrument of Accession substantially in the form attached as Exhibit I hereto (each a ?Fund? and collectively, the ?Funds?).
April 25, 2017	EX-99.2J CUST CONTR	AGREEMENT BETWEEN STATE STREET BANK AND TRUST COMPANY EACH OF THE INVESTMENT COMPANIES LISTED ON SCHEDULE A ATTACHED HERETO Table of Contents Exhibit (j) AGREEMENT BETWEEN STATE STREET BANK AND TRUST COMPANY AND EACH OF THE INVESTMENT COMPANIES LISTED ON SCHEDULE A ATTACHED HERETO Table of Contents ARTICLE I.
April 25, 2017	486BPOS	As filed with the Securities and Exchange Commission on April 25 , 2017 Securities Act Registration No. 333-210770 Investment Company Act Registration No. 811-21702 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2 ☒ Re As filed with the Securities and Exchange Commission on April 25 , 2017 Securities Act Registration No.
April 3, 2017	CORRESP	BlackRock Enhanced Capital & Income Fund ESP DIRECT DIAL 617-573-4836 DIRECT FAX 617-305-4836 EMAIL ADDRESS [email protected] Skadden, Arps, Slate, Meagher & Flom llp 500 BOYLSTON STREET BOSTON, MASSACHUSETTS 02116 TEL: (617) 573-4800 FAX: (617) 573-4822 www.skadden.com April 3, 2017 FIRM/AFFILIATE OFFICES - CHICAGO HOUSTON LOS ANGELES NEW YORK PALO ALTO WASHINGTON, D.C. WILMINGTON - BEIJING BRUSSELS FRANKFURT HONG KONG LONDON MOSCO
February 14, 2017	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
November 22, 2016	N-Q	BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) N-Q 1 d260685dnq.htm BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent
November 22, 2016	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
October 28, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 (October 28, 2016) BLACKROCK HEALTH SCIENCES TRUST (Exact Name of Registrant as Specified in Charter) DELAWARE 811-21702 20-2433262 (State or Other Jurisdiction o
October 28, 2016	EX-3.1	Amended and Restated Bylaws of the Registrant, dated October 28, 2016 is incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8-K, as filed with the SEC on October 28, 2016. EX-3.1 Exhibit 3.1 BLACKROCK HEALTH SCIENCES TRUST AMENDED AND RESTATED BYLAWS Effective as of October 28, 2016 TABLE OF CONTENTS Page ARTICLE I SHAREHOLDER MEETINGS Section 1. Chair 1 Section 2. Annual Meetings of Shareholders 1 Section 3. Special Meetings of Shareholders 1 Section 4. Place of Meetings 2 Section 5. Notice of Meetings 2 Section 6. Nature of Business at Annual Meetings of Sharehold
June 9, 2016	DEF 14A	BlackRock Health Sciences Trust BLACKROCK PROXY STATEMENT BLACKROCK PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 7, 2016	CORRESP	BlackRock Health Sciences Trust ESP corresp.htm BlackRock Investments, LLC 55 East 52nd Street New York, NY 10055 June 7, 2016 VIA EDGAR John Grzeskiewicz Division of Investment Management U.S. Securities and Exchange Commission 100 F Street N.E. Washington, DC 20549 RE: BlackRock Health Sciences Trust File Nos. 333-210770 & 811-21702 Dear Mr. Grzeskiewicz: Pursuant to Rule 461 of the General Rules and Regulations under the Securiti
June 7, 2016	CORRESP	BlackRock Health Sciences Trust ESP corresp.htm BlackRock Health Sciences Trust 100 Bellevue Parkway Wilmington, DE 19809 June 7, 2016 VIA EDGAR John Grzeskiewicz Division of Investment Management U.S. Securities and Exchange Commission 100 F Street N.E. Washington, DC 20549 RE: BlackRock Health Sciences Trust File Nos. 333-210770 & 811-21702 Dear Mr. Grzeskiewicz: Pursuant to Rule 461 of the General Rules and Regulations under the
May 23, 2016	N-Q	BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 23, 2016	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
April 1, 2016	EX-24	POWER OF ATTORNEY Unassociated Document POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints Janey Ahn, Benjamin Archibald, Eugene Drozdetski, Laura Ingle, Gladys Chang, Charles Park, Tricia Meyer and Howard Surloff of BlackRock, Inc.
March 2, 2016	EX-24	POWER OF ATTORNEY Unassociated Document POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints Janey Ahn, Benjamin Archibald, Eugene Drozdetski, Laura Ingle, Gladys Chang, Charles Park, Tricia Meyer and Howard Surloff of BlackRock, Inc.
February 16, 2016	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
November 24, 2015	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
November 24, 2015	N-Q	BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) N-Q 1 d93388dnq.htm BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent f
June 12, 2015	DEF 14A	BlackRock New York Municipal 2018 Term Trust BLACKROCK PROXY STATEMENT CLASSIFIED BOARD DEF 14A 1 d939579ddef14a.htm BLACKROCK PROXY STATEMENT CLASSIFIED BOARD Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Co
May 22, 2015	EX-99.CERT	CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF Certification Pursuant to Section 302 EX-99.CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report
May 22, 2015	N-Q	BlackRock Health Sciences Trust BLACKROCK HEALTH SCIENCES TRUST (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: John M. Perlowski, Chief Executive Offic
May 11, 2015	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) April 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 13, 2015	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 16, 2015	CORRESP	MYD / BlackRock Muniyield Fund, Inc. CORRESP - - CORRESP 1 filename1.htm Skadden, Arps, Slate, Meagher & Flom llp 500 BOYLSTON STREET BOSTON, MASSACHUSETTS 02116 TEL: (617) 573-4800 FAX: (617) 573-4822 www.skadden.com January 16, 2015 FIRM/AFFILIATE OFFICES - CHICAGO HOUSTON LOS ANGELES NEW YORK PALO ALTO WASHINGTON, D.C. WILMINGTON - BEIJING BRUSSELS FRANKFURT HONG KONG LONDON MOSCOW MUNICH PARIS SÃO PAULO SEOUL SHANGHAI SINGAPORE SYDNEY TOKYO
November 10, 2014	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 07)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) November 10, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
September 25, 2014	EX-99.CERT	CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF Certification Pursuant to Section 302 EX-99.CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report
September 25, 2014	N-Q	Blackrock Health Sciences Trust - BLACKROCK HEALTH SCIENCES TRUST N-Q 1 d747296dnq.htm BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent
June 13, 2014	DEFA14A	- BLACKROCK BUILD AMERICA BOND TRUST DEFA14A 1 d742131ddefa14a.htm BLACKROCK BUILD AMERICA BOND TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of th
June 13, 2014	DEF 14A	- BLACKROCK PROXY STATEMENT CLASSIFIED BOARD DEF 14A 1 d737732ddef14a.htm BLACKROCK PROXY STATEMENT CLASSIFIED BOARD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Us
March 25, 2014	N-Q	Quarterly Schedule of Portfolio Holdings - BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: John M. Perlowski, Chief Executive Offic
March 25, 2014	EX-99.CERT	EX-99. CERT CERTIFICATION PURSUANT TO SECTION 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
February 14, 2014	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 06)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
December 11, 2013	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* BlackRock Health Sciences Trust (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) November 30, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
September 24, 2013	N-Q	Quarterly Schedule of Portfolio Holdings - BLACKROCK HEALTH SCIENCES TRUST BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 24, 2013	EX-99.CERT	CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF Certification Pursuant to Section 302 EX-99.CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report
June 13, 2013	DEF 14A	- BLACKROCK PROXY STATEMENT CLASSIFIED BOARD BLACKROCK PROXY STATEMENT CLASSIFIED BOARD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 26, 2013	N-Q	Quarterly Schedule of Portfolio Holdings - BLACKROCK HEALTH SCIENCES TRUST BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 26, 2013	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
February 14, 2013	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - BLACKROCK HEALTH SCIENCES TRUST 13G/A4 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* BLACKROCK HEALTH SCIENCES TRUST (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
January 29, 2013	CORRESP	- 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 January 29, 2013 Via EDGAR Laura Hatch Division of Investment Management Securities and Exchange Commission 100 F Street, NE Washington, D.
December 7, 2012	CORRESP	- 787 Seventh Avenue New York, NY 10019-6099 Tel: 212 728 8000 Fax: 212 728 8111 December 7, 2012 Via EDGAR Laura Hatch Division of Investment Management Securities and Exchange Commission 100 F Street, NE Washington, D.
September 25, 2012	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
September 25, 2012	N-Q	Quarterly Schedule of Portfolio Holdings - BLACKROCK HEALTH SCIENCES TRUST (BME) BlackRock Health Sciences Trust (BME) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 12, 2012	DEFR14A	- CLASSIFIED FUND NOTICE AND PROXY CLASSIFIED FUND NOTICE AND PROXY Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 11, 2012	DEF 14A	- CLASSIFIED FUND NOTICE AND PROXY Classified Fund Notice and Proxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 26, 2012	EX-99.CERT	CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE Certification Pursuant to Section 302 EX-99.CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report
March 26, 2012	N-Q	Quarterly Schedule of Portfolio Holdings - BLACKROCK HEALTH SCIENCES TRUST (BME) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: John M. Perlowski, Chief Executive Office
February 14, 2012	SC 13G/A	BME / BlackRock Health Sciences Trust / BANK OF AMERICA CORP /DE/ - BLACKROCK HEALTH SCIENCES TRUST 13GA3 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* BLACKROCK HEALTH SCIENCES TRUST (Name of Issuer) Common Stock (Title of Class of Securities) 09250W107 (CUSIP Number) December 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
September 26, 2011	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
September 26, 2011	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY BlackRock Health Sciences Trust (BME) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 16, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant \|X\| Filed by a Party other than the Registrant \|\| Check the appropriate box: \|\| Preliminary Proxy Statement \|\| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) \|X\| Def
June 16, 2011	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant \|X\| Filed by a Party other than the Registrant \|\| Check the appropriate box: \|\| Preliminary Proxy Statement \|\| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) \|\| Defi
April 20, 2011	EX-24	POWER OF ATTORNEY POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints Howard Surloff, Janey Ahn, Edward Baer, Douglas McCormack, Aaron Wasserman, Ben Archibald and Noah Gellner of BlackRock, Inc.
March 29, 2011	EX-99.CERT	EX-99. CERT Certification Pursuant to Section 302 EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this repor
March 29, 2011	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY BlackRock Health Sciences Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 14, 2011	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* BLACKROCK HEALTH SCIENCES TRUST (Name of Issuer) COMMON STOCK (Title of Class of Securities) (CUSIP Number) December 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* BLACKROCK HEALTH SCIENCES TRUST (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
February 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2011 BlackRock Health UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2011 BlackRock Health Sciences Trust (Exact Name of Registrant as Specified in Charter) DELAWARE 811-21702 20-2433262 (State or Other Jurisdiction of Incorporation) (Commi
February 4, 2011	EX-99.1	BlackRock Closed-End Funds Announce Date of 2011 Annual Meeting of Shareholders Exhibit 99.1 Contact: 1-800-882-0052 BlackRock Closed-End Funds Announce Date of 2011 Annual Meeting of Shareholders New York, February 4, 2011— The BlackRock Closed-End Funds listed below (each a "Fund" and collectively, the "Funds") announced today that each of their 2011 annual meetings of shareholders will be held on July 28, 2011. Additional information regarding deadlines for shareholder pro
December 29, 2010	EX-99.77Q1(A)	BlackRock Health Sciences Trust c63715ex99-77q1a.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing Exhibit 99.77Q1(a) BlackRock Health Sciences Trust 77Q1(a): Copies of material amendments to Registrant’s by-laws Amended and Restated By-Laws of the Registrant is hereby incorporated by reference to the Registrant’s Form 8-K filed on October 29, 2010 (SEC Accession No. 0001193125-10-240179 (34 Act)
December 29, 2010	EX-99.77B	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM c63715ex99-77b.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing Exhibit 99.77B REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Trustees of BlackRock Health Sciences Trust: In planning and performing our audit of the financial statements of BlackRock Health Sciences Trust (the “Trust”) as of and for the year ended October 31
October 29, 2010	EX-3.1	BLACKROCK HEALTH SCIENCES TRUST AMENDED AND RESTATED Effective as of October 28, 2010 TABLE OF CONTENTS Page ARTICLE I SHAREHOLDER MEETINGS Section 1. Chair 1 Section 2. Annual Meetings of Shareholders 1 Section 3. Special Meetings of Shareholders 1 BLACKROCK HEALTH SCIENCES TRUST AMENDED AND RESTATED BYLAWS Effective as of October 28, 2010 TABLE OF CONTENTS Page ARTICLE I SHAREHOLDER MEETINGS Section 1.
October 29, 2010	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d8k.htm BLACKROCK HEALTH SCIENCES TRUST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2010 (October 25, 2010) BlackRock Health Sciences Trust (Exact name of registrant as specified in its charter) DELAWARE 811-2
September 28, 2010	EX-99.CERT	EX-99. CERT EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anne F. Ackerley, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement
September 28, 2010	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: Anne F. Ackerley, Chief Executive Officer
July 23, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant \|X\| Filed by a Party other than the Registrant \|\| Check the appropriate box: \|\| Preliminary Proxy Statement \|\| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) \|X\| Def
March 29, 2010	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: Anne F. Ackerley, Chief Executive Officer
March 29, 2010	EX-99.CERT	EX-99. CERT EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anne F. Ackerley, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement
February 1, 2010	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1)* BLACKROCK HEALTH SCIENCES TRUST ___________________________________________________________ (Name of Issuer) COMMON STO SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1)* BLACKROCK HEALTH SCIENCES TRUST (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09250W107 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedu
September 28, 2009	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: Anne F. Ackerley, Chief Executive Officer
September 28, 2009	EX-99.CERT	EX-99. CERT EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anne F. Ackerley, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement
August 10, 2009	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant \|X\| Filed by a Party other than the Registrant \|\| Check the appropriate box: \|\| Preliminary Proxy Statement \|\| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) \|X\| Sup
July 17, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant \|X\| Filed by a Party other than the Registrant \|\| Check the appropriate box: \|\| Preliminary Proxy Statement \|\| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) \|X\| Def
March 31, 2009	EX-99.CERT	EX-99. CERT - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald C. Burke, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trus
March 31, 2009	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 N
October 7, 2008	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k.htm FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2008 (May 30, 2008) BlackRock Health Sciences Trust (Exact name of registrant as specified in its charter) DELAWARE 811-21702 20-2433262 (State or
October 7, 2008	EX-3.1	BLACKROCK HEALTH SCIENCES TRUST AMENDED AND RESTATED Effective as of May 29, 2008 TABLE OF CONTENTS Exhibit 3.1 BLACKROCK HEALTH SCIENCES TRUST AMENDED AND RESTATED BYLAWS Effective as of May 29, 2008 TABLE OF CONTENTS Page ARTICLE I SHAREHOLDER MEETINGS Section 1. Chairman 2 Section 2. Annual Meetings of Shareholders 2 Section 3. Special Meetings of Shareholders 2 Section 4. Place of Meetings 2 Section 5. Notice of Meetings 2 Section 6. Conduct of Meetings 4 Section 7. Adjournments 4 Section 8.
September 26, 2008	EX-99.CERT	EX-99. CERT EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald C. Burke, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement
September 26, 2008	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: Donald C. Burke, Chief Executive Officer,
July 31, 2008	DEF 14A	IMPORTANT NEWS FOR FUND SHAREHOLDERS August 1, 2008 Dear Shareholder: A joint annual meeting of the BlackRock closed-end funds listed in Appendix A to the enclosed proxy statement (each a “Fund”) will be held at the offices of BlackRock Advisors, LLC, Park Avenue Plaza, 55 East 52nd Street, 11th Floor, New York, New York 10055, on Friday, September 12, 2008, at 12:30 p.
March 26, 2008	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust (BME) Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809 Name and address of agent for service: Donald C. Burke, Chief Executive Officer,
March 26, 2008	EX-99.CERT	EX-99. CERT EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Donald C. Burke, Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement
September 24, 2007	EX-99.CERT	EX-99. CERT c50352ex99cert.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing EX-99. CERT CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert S. Kapito, President (principal executive officer) of BlackRock Health Sciences Trust, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Science
September 24, 2007	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY c50352nq.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-21702 Name of Fund: BlackRock Health Sciences Trust Fund Address: 100 Bellevue Parkway, Wilmington, DE
July 17, 2007	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 BlackRock SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement.
July 5, 2007	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement.
July 2, 2007	DEFA14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement.
July 2, 2007	DEF 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 BLACKROCK Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement.
June 15, 2007	PRE 14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement.
May 31, 2007	EX-99.1	Certain BlackRock Closed-End Funds Announce Shareholder Proposal Submission Date Contact: 1-800-882-0052 Certain BlackRock Closed-End Funds Announce Shareholder Proposal Submission Date New York, May 30, 2007 ? The BlackRock Closed-End Funds listed below (each a ?Trust? and collectively, the ?Trusts?) announced today that their annual meetings of shareholders will be held no later than September 30, 2007.
May 31, 2007	8-K	Financial Statements and Exhibits 8-K 1 e21866-458k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2007 BLACKROCK HEALTH SCIENCES TRUST (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporati
March 29, 2007	EX-99.CERT	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER CERTIFICATIONS c47521ex99-cert.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing EX-99.CERT CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER CERTIFICATIONS I, Robert S. Kapito, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma
March 29, 2007	N-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number:811-21702 BlackRock Health Sciences Trust (Exact name of registrant as specified in charter) 100 Bellevue Parkway, Wilmington, DE 19809 (Address of principal executive offices) (Zip code) Robert S. K
September 29, 2006	N-Q	BlackRock Health Sciences Trust (Exact name of registrant as specified in charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 BlackRock Health Sciences Trust (Exact name of registrant as specified in charter) 100 Bellevue Parkway, Wilmington, DE 19809 (Address of principal executive offices) (Zip code) Robert S.
September 29, 2006	EX-99.CERT	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER EX-99.CERT CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER CERTIFICATIONS I, Robert S. Kapito, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s
July 20, 2006	DEFA14A	IMPORTANT NOTICE REGARDING YOUR INVESTMENT IN BLACKROCK CLOSED-END FUNDS 100 Bellevue Parkway Wilmington, Delaware 19809 PLEASE CAST YOUR VOTE TODAY IMPORTANT NOTICE REGARDING YOUR INVESTMENT IN BLACKROCK CLOSED-END FUNDS 100 Bellevue Parkway Wilmington, Delaware 19809 Dear Shareholder: Recently we sent you proxy material regarding the joint Special Meeting of Shareholders for the BlackRock Closed-End Funds to take place on August 23, 2006.
June 22, 2006	DEFA14A	Proposed Open End-Fund Family as of October 2006 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 20, 2006	DEFR14A	BLACKROCK CLOSED-END FUNDS PROXY STATEMENT FOR JOINT SPECIAL MEETING OF STOCKHOLDERS/SHAREHOLDERS TO BE HELD ON AUGUST 23, 2006 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 20, 2006	COVER	Securities and Exchange Commission SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE FIRM/AFFILIATE NEW YORK 10036-6522 OFFICES - TEL: (212) 735-3000 BOSTON FAX: (212) 735-2000 CHICAGO www.
June 16, 2006	COVER	SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK 10036-6522 TEL: (212) 735-3000 FAX: (212) 735-2000 www.skadden.com SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK 10036-6522 TEL: (212) 735-3000 FAX: (212) 735-2000 www.
June 16, 2006	DEF 14A	BLACKROCK CLOSED-END FUNDS PROXY STATEMENT FOR JOINT SPECIAL MEETING OF STOCKHOLDERS/SHAREHOLDERS TO BE HELD ON AUGUST 23, 2006 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 26, 2006	PRE 14A	[PRELIMINARY COPY – SUBJECT TO COMPLETION] SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 26, 2006	COVER	End Funds SKADDEN , ARPS , SLATE , MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK 10036-6522 FIRM/AFFILIATE OFFICES - BOSTON CHICAGO HOUSTON LOS ANGELES PALO ALTO SAN FRANCISCO WASHINGTON, D.
April 19, 2006	DEF 14A	BLACKROCK CLOSED-END FUNDS 100 BELLEVUE PARKWAY WILMINGTON, DELAWARE 19809 NOTICE OF JOINT ANNUAL MEETING OF STOCKHOLDERS/SHAREHOLDERS TO BE HELD ON MAY 23, 2006 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 3, 2006	EX-99.CERT	CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER EX-99.CERT CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER CERTIFICATIONS I, Robert S. Kapito, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s
April 3, 2006	N-Q	FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 BlackRock Health Sciences Trust (Exact name of registrant as specified in charter) 100 Bellevue Parkway, Wilmington, DE 19809 (Address of principal executive offices) (Zip code) Robert S.
March 29, 2006	PRE 14A	BLACKROCK CLOSED-END FUNDS 100 BELLEVUE PARKWAY WILMINGTON, DELAWARE 19809 NOTICE OF JOINT ANNUAL MEETING OF STOCKHOLDERS/SHAREHOLDERS TO BE HELD ON MAY 23, 2006 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
September 29, 2005	N-Q	FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-21702 BlackRock Health Sciences Trust (Exact name of registrant as specified in charter) 100 Bellevue Parkway, Wilmington, DE 19809 (Address of principal executive offices) (Zip code) Robert S.
September 29, 2005	EX-99.CERT	CERTIFICATIONS EX-99.CERT CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER CERTIFICATIONS I, Robert S. Kapito, certify that: 1. I have reviewed this report on Form N-Q of BlackRock Health Sciences Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s
March 29, 2005	EX-99.(L)	SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK, NY 10036-6522 (212) 735-3000 March 29, 2005 QuickLinks - Click here to rapidly navigate through this document Exhibit 99(l) SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK, NY 10036-6522 (212) 735-3000 March 29, 2005 BlackRock Health Sciences Trust 100 Bellevue Parkway Wilmington, Delaware 19809 Re: BlackRock Health Sciences Trust Registration Statement on Form N-2 Ladies and Gentlemen: We have acted as special counsel to BlackRock Health Sciences Trust, a statutory trust created under the Delaware Statutory Trust Act (the "Trust"), in connection with the issuance and sale by the Trust of up to 425,000 shares (including shares subject to an over-allotment option) of the Trust's common shares of beneficial interest, par value $.
March 29, 2005	EX-99.(N)	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.(N) 3 a2154766zex-99n.htm EXHIBIT 99.(N) QuickLinks - Click here to rapidly navigate through this document Exhibit 99(n) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in this Amendment No. 3 to the Registration Statement of BlackRock Health Sciences Trust on Form N-2 (Investment Company Act Registration No. 811-21702), which is also a new Registration Stateme
March 29, 2005	N-2MEF	As filed with the Securities and Exchange Commission on March 29, 2005 QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on March 29, 2005 Securities Act Registration No.

BME / BlackRock Health Sciences Trust - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)